Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 16/20 | 0.73 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423269 | 0.87 | APP (0.81) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL13806269 | 0.86 | APP (0.70) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL9238817 | 0.84 | APP (1.00) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL29385461 | 0.82 | APP (0.72) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL10032146 | 0.82 | APP (0.72) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL2036269 | 0.81 | APP (1.00) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL2922465 | 0.81 | APP (0.72) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL1572293 | 0.81 | APP (0.72) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL3237813 | 0.81 | APP (0.71) | APPSULT1A1MAPTTP53THRB | |
| SCHEMBL10311762 | 0.80 | APP (0.70) | APPSULT1A1MAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090142269-A1 | ISOTOYPICALLY-LABELED BENZOTHIAZOLE COMPOUNDS AS IMAGING AGENTS FOR AMYLOIDOGENIC PROTEINS | UNIVERSITY OF OITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-06-04 | — | — | US | disclosed |
| US-20090142269-A1 | ISOTOYPICALLY-LABELED BENZOTHIAZOLE COMPOUNDS AS IMAGING AGENTS FOR AMYLOIDOGENIC PROTEINS | UNIVERSITY OF OITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142269-A1 | ISOTOYPICALLY-LABELED BENZOTHIAZOLE COMPOUNDS AS IMAGING AGENTS FOR AMYLOIDOGENIC PROTEINS | MAPT, TSPO, APP | APP 3/4885SULT1A1 917/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.